Contact us  |  Disclaimer  |  Sitemap
  • ABOUT US
  • MISSION & VALUES
  • BUSINESS STRATEGY
  • OUR HISTORY
  • MANAGEMENT
  • BOARD OF DIRECTORS
  • SCIENTIFIC ADVISORY BOARDS
  • CORPORATE GOVERNANCE
    • GOVERNANCE DOCUMENTS
    • RISK MANAGEMENT
  • CAREERS
ABOUT US
  • PRODUCTS
  • LCP-Tacro™
    • Why immunosuppression?
    • About organ transplantations
    • MARKET OVERVIEW
    • Product programs
    • Development strategy and status
    • Commercial strategy
  • Cardiovascular
PRODUCTS
  • TECHNOLOGY
  • MELTDOSE® TECHNOLOGY PLATFORM
  • INTELLECTUAL PROPERTY RIGHTS
TECHNOLOGY
  • INVESTOR RELATIONS
  • RELEASES
  • DOWNLOAD CENTER
  • CALENDAR
  • FINANCIAL INFORMATION
    • OUTLOOK
  • STOCK INFORMATION
    • HISTORIC STOCK LOOKUP
    • INVESTMENT CALCULATOR
    • ORDER DEPTH AND LATEST TRADES
    • DIVIDEND HISTORY
    • ANALYST COVERAGE
  • General Meetings
INVESTOR
  • MEDIA
MEDIA

Improving Treatments - Improving Lives


Veloxis Pharmaceuticals (Veloxis) is a speciality pharmaceutical company focused on the development of LCP-Tacro for the prevention of organ rejection in kidney transplant patients.



LATEST RELEASES

May 30, 2013
Veloxis Pharmaceuticals A/S — annulment of warrants and registration of new Articles of Association pursuant thereto

May 21, 2013
European Medicines Agency (EMA) Accepts Veloxis' Marketing Authorization Application (MAA) for LCP-Tacro for Treatment of Kidney Transplant Patients

May 20, 2013
Final STRATO Clinical Study Data Demonstrates Potential for LCP-TacroTM to Improve Tacrolimus-Induced Tremors

May 15, 2013
Veloxis Pharmaceuticals announces financial results for the first three months of 2013

Stock Information

QUICK LINKS

Releases

About LCP-Tacro™

Outlook

Corporate Governance

Our Management Team

Analyst Coverage

Rights Issue 2012

 

 

Shareholder Briefcase

email alerts

download library

snapshot

mobile investor

RSS News Feeds

Print Page

Email Page

Share this on: Close window
delicious Delicious
Digg Digg
Facebook Facebook
LinkedIn LinkedIn
Twitter Twitter
What is this?

Veloxis Pharmaceuticals A/S | Bøge Allé 5, 2th | DK-2970 Hørsholm | Tel. +4570333300 | CVR-no. 26 52 77 67 | info@veloxis.com